Clinical

CLINUVEL
Posted by CLINUVEL
March 17, 2023

DNA Repair data presented at American Academy of Dermatology Meeting

First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...

Read More
CLINUVEL
Posted by CLINUVEL
February 14, 2023

PRÉNUMBRA® Formulation Completed For Clinical Trial Use

CLINUVEL today announced the completion of manufacture of the first cGMP batch...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note

Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

Results released today from a clinical study have shown that the drug...

Read More
CLINUVEL
Posted by CLINUVEL
February 2, 2023

Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population

Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage

Results from a clinical trial in a genetic DNA repair disorder show...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note

Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2023

Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum

First Phase II results show decrease in UV-induced skin damage

Read More
CLINUVEL
Posted by CLINUVEL
October 20, 2022

First vitiligo patient enrolled in afamelanotide monotherapy study

CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...

Read More
Lachlan Hay
Posted by Lachlan Hay
September 5, 2022

CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients

European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...

Read More
CLINUVEL
Posted by CLINUVEL
July 28, 2022

PRÉNUMBRA® for stroke

Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo treatment program

A new potential therapy for the pigment loss disorder vitiligo will undergo...

Read More
CLINUVEL
Posted by CLINUVEL
May 4, 2022

Positive final results in stroke

CLINUVEL today released positive final results of the open label pilot study...

Read More
Lachlan Hay
Posted by Lachlan Hay
April 1, 2022

CLINUVEL Extends Employment Agreement With CEO

CLINUVEL today announced that it has extended the Employment Agreement with the...

Read More
CLINUVEL
Posted by CLINUVEL
April 1, 2022

DNA Repair Communiqué II

In this DNA Repair Communiqué II we delve deeper into the topic...

Read More